Sahu Geetanjali, Chandy Anish, Sahu Raju
Email ID Not Available
Sahu Geetanjali*, Chandy Anish, Sahu Raju
School of Pharmacy, Chouksey Engineering College, Lalkhadan, Bilaspur, Chhattisgarh, India.
Volume - 14,
Issue - 1,
Year - 2022
Delivering a drug to eye has been a major challenge to pharmacologists and drug delivery scientists (Gaudana et al 2010). It is due to its complex structure and unique anatomy and physiology. This results only small portion of drug reaches to the site of action. The eye contains two main chambers, anterior chamber and posterior chamber (Chen et al., 2018). As the renewal time of tear fluid is less than 5 minutes (Mishima, Gusset et al., 1996) ophthalmic drug washout very quickly from anterior portion of cornea. To prevail over with this issue various formulations strategies have been investigated to increase ocular drug retention. In ophthalmic formulations the suspension is better option for incorporating poorly soluble active pharmaceutical ingredients. As ophthalmic suspension improvise drug delivery by enhancing retention time of drug, thereby increasing the bioavailability of the drug. In this review we will discuss about the important parameters that are considered in the formulation of ophthalmic suspension.
Cite this article:
Sahu Geetanjali, Chandy Anish, Sahu Raju. A Brief Review on Ophthalmic Suspension for Covid-19 Infection. Research Journal of Pharmacology and Pharmacodynamics.2022;14(1):29-6. doi: 10.52711/2321-5836.2022.00005
Sahu Geetanjali, Chandy Anish, Sahu Raju. A Brief Review on Ophthalmic Suspension for Covid-19 Infection. Research Journal of Pharmacology and Pharmacodynamics.2022;14(1):29-6. doi: 10.52711/2321-5836.2022.00005 Available on: https://rjppd.org/AbstractView.aspx?PID=2022-14-1-5
1. Vo Anh, Feng Xin, Patel Deval, Mohammad Adil, Kozak Darby, Choi Stephanie, Mohammad Ashraf and Xi Xiaoming, (2020). Factors affecting the particle size distribution and rheology of brinzolamide ophthalmic suspension. International journal of pharmaceutics, Aug30;586:119495.
2. Bartlett, J.D., Ophthalmic Drug Delivery. In Clinical Ocular Pharmacology; 3rd Ed.; Barlett, J.D., Jaanus, S.D., Eds.; Lea & Febiger: Philadelphia, 1995; 47-74.
3. Bracko Danka, Cizmek- Centina Biserka, Miocic Sandra and Tunjic Iva (2012). Ophthalmic Formulations and Processes for their Preparations. Patent Application Publication.
4. Mathhews, B.R. (1999). Regulatory aspects of stability testing in Europe, Drug Dev. Ind. Pharm., 25(7), 831-856.
5. Brian, R., Matthews and Wall Michael, G., (2000). Stability Storage and Testing of Ophthalmic Products for Global Registration, Drug Development and Industrial Pharmacy, 26:12, 1227-1237.
6. CPMP/ICH/380/95, Note for Guidance on Stability Testing of New Drug Substances and Products. Available online at: http://www.eudra.org/humandocs/humans/ich.htm
7. Demichev et al., 2021, A time resolved proteomic and prognostic map of COVID-19, Cell systems-12, 1-15, ElsevierInc. https://doi.org/10.1016/j.cels.2021.05.005
8. Diestelhorst, M., Kwon, K.A., Suverkrup, R. (1998). Dose uniformity of ophthalmic suspensions. J Cataract Refract Surg. May, 24(5): 672-7.
9. Drs. Horby, Lim, Emberson, Haynes and Landray (2020). Dexamethasone in hospitalized patients with Covid-19- preliminary report. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2021436
10. Frederick, K.J. (1961). Performance and Problems of Pharmaceutical Suspensions. J. Pharm. Sci., 50, 531-535.
11. Gennaro, A.R. and Easton, P.A. (1990). Remington’s Pharmaceutical science, 19th edition, Mack Publishing: pp 1563-1573.
12. Guidance for Industry, Stability Testing of Drug Substances and Drug Products. FDA Draft (not for implementation). Available online at: http://www.fda.gov/cder/guidance/index.htm
13. Hao Chen, Yingying Jin, Lin Sun, Xi Li, Kaihui Nan, Haihua Liu, Qinxiang Zheng and Bailiang Wang (2018). Recent developments in ophthalmic drug delivery systems for therapy of both anterior and posterior segment diseases. Colloid and interface science communication, 24, 54-61.
14. Hecht, G. (1995). Ophthalmic preparation. In Gennaro AR (Editor). Remington: The Science and Practice of Pharmacy. Edition 19, Mack Publishing Co., Eastern PA, USA, chapter 89, pp. 1563-1573.
15. Hecht, G. (1995). Ophthalmic Preparations. In Remington: The Science and Practice of Pharmacy; 19th Ed.; Gennaro, A.R.; Ed.; Mack Publ. Co.: Easton, PA, 1563-1568.
16. ICH draft consensus guideline, Stability testing of new drug substances and products, released at Step 2 of the ICH process on October 7, 1999, by the ICH Steering Committee. Available online at: http://www.ifpma.org/ich5q.html
17. International Conference on Harmonisation, Guideline on Stability Testing of New Drug Substances and Products, Fed. Reg., 59(183), 48754-48759 (1994).
18. Kass, M.A., Hodapp, E., Gordon, M., Kolker, A.E., and Goldberg. Patient Administration of Eyedrops: Observation, Part. Ann. Ophthalmol. (1982). 14, 889-893.
19. Keni R, Alexander, Mudgal and Nandkumar K(2020), COVID-19: emergence, spread, possible treatments and global burden. Front. PublicHealth 8:216.doi:10.3389/fpubh.2020.00216
20. Kompella, U.B., Kadam R.S. and Lee VH (2010). Recent advances in ophthalmic drug delivery. Therapeutic delivery. Sep; 1(3): 435-56.
21. Kramer, A. and Behrens-Baumann, W. (2002).Antiseptic prophylaxis and therapy in ocular infections . Dev ophthalmol, 33:85-116.
22. Lippmann, O. (1957). Local Irritating Effect Caused by Topical Use of Steroids in the Eye. AMA Arch. Ophthalmol. 57, 339-344.
23. Muhlemann B et al., Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study, Clinical Microbiology and Infection, http://doi.org/10.1016/j.cmi.2021.06.008.
24. Schoenwald, R.D. and Stewart, P. (1980) Effect of Particle Size on Ophthalmic Bioavailability of Dexamethasone Suspensions in Rabbits. J. Pharm. Sci., 69, 391-394.
25. Sieg, J.W. and Robinson, J.R. Vehicle Effects on Ocular Drug Bioavailability: Evaluation of Flurometholone. J. Pharm. Sci. 1975, 64, 931-936.
26. Tuomela, A., Liu, P., Puranen, J., Ronkko, S., Laaksonen, T., Kalesnykas, G., Oksala, O., Ilkka, J., Laru, J., Jarvinen, K., Hirvonen, J. and Peltonen, L. (2014). “Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo.” Int J Pharm 467(1-2): 34-41.
27. Uddin, M., Mamun, A., Kabir, M., Setu, J., Zaman, S., Begum, Y. and Amran, M. (2017). “Quality Control Tests for Ophthalmic Pharmaceuticals: Pharmacopoeial Standards and Specifications.” Journal of Advances in Medical and Pharmaceutical Sciences 14(2): 1-17.
28. Vooturi and Sunil (2020). “Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid.” Journal of ocular pharmacology and therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics vol. 36.6: 404-409.